Anchored in work undertaken by a father and son team at Purdue and subsequently licenced by the firm, Novosteo had from early on been organized around reduction of the morbidity, mortality and loss of productivity associated with bone fractures. Based on discoveries of agents that accelerate bone regeneration and breakthroughs in methods to target these agents selectively to fracture surfaces, Novosteo has designed a series of fracture-targeted drugs that concentrate a drug's healing power specifically at the fracture site, thereby greatly accelerating and improving the healing process. In May 2022 it was announced that Cortexyme had successfully completed acquisition of Novosteo - an achievement that expands Cortexymeâs pipeline into rare disease indications with the addition of Novosteoâs NOV004, a bone-targeting molecule aimed at speeding up fracture repair. The drug is expected to enter phase 1 clinical studies in 202 - the plan being to progress to a lead indication in osteogenesis imperfecta, an inherited bone disorder also known as brittle bone disea
